Targeting Sp1 transcription factor in prostate cancer therapy

Umesh T. Sankpal, Steven Goodison, Maen Abdelrahim, Riyaz Basha

Research output: Contribution to journalReview article

83 Citations (Scopus)

Abstract

Transcription factors are proteins that regulate gene expression by binding to specific DNA sequences within gene promoter regions. Specificity protein (Sp) family transcription factors play a critical role in various cellular processes and have been shown to be associated with tumorigenesis. The Sp family consists of several members that contain a highly conserved DNA-binding domain composed of three zinc fingers at the C-terminus and serine/threonine-and glutamine-rich transactivation domains at the N-terminal. Sp1 is elevated in several malignancies including prostate cancer and is associated with the prognosis of patients. Sp1, Sp3, and Sp4 regulate a variety of cancer associated genes that are involved in cell cycle, proliferation, cell differentiation, and apoptosis. Studies have shown that in prostate cancer, Sp1 regulates important genes like androgen receptor, TGF-β, c-Met, fatty acid synthase, matrix metalloprotein (MT1-MMP), PSA, and α-integrin. These results highlight the importance of Sp1 in prostate cancer and emphasize the potential therapeutic value of targeting Sp1. Several strategies, including the use of natural and synthetic compounds, have been used to inhibit Sp1 in prostate cancer. These include polyphenol quercetin, betulinic acid, acetyl-11-keto-beta-boswellic acid, tea phenols, isothiocyanates, thiazolidinediones, arsenic trioxide, and selenium. This review will describe the association of Sp1 in prostate cancer with a special emphasis on some of the agents tested to target Sp1 for the treatment of this malignancy.

Original languageEnglish (US)
Pages (from-to)518-525
Number of pages8
JournalMedicinal Chemistry
Volume7
Issue number5
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

Fingerprint

Sp1 Transcription Factor
Prostatic Neoplasms
Sp Transcription Factors
Metalloproteins
Isothiocyanates
Matrix Metalloproteinase 14
Therapeutics
Thiazolidinediones
Fatty Acid Synthases
Phenols
Neoplasm Genes
Zinc Fingers
Quercetin
Androgen Receptors
Polyphenols
Tea
Threonine
Selenium
Glutamine
Genetic Promoter Regions

Keywords

  • Cancer therapy
  • Prostate cancer
  • PSA
  • Sp transcription factors

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Targeting Sp1 transcription factor in prostate cancer therapy. / Sankpal, Umesh T.; Goodison, Steven; Abdelrahim, Maen; Basha, Riyaz.

In: Medicinal Chemistry, Vol. 7, No. 5, 01.09.2011, p. 518-525.

Research output: Contribution to journalReview article

Sankpal, Umesh T. ; Goodison, Steven ; Abdelrahim, Maen ; Basha, Riyaz. / Targeting Sp1 transcription factor in prostate cancer therapy. In: Medicinal Chemistry. 2011 ; Vol. 7, No. 5. pp. 518-525.
@article{f03f117a52614fcaba3400368950d3b2,
title = "Targeting Sp1 transcription factor in prostate cancer therapy",
abstract = "Transcription factors are proteins that regulate gene expression by binding to specific DNA sequences within gene promoter regions. Specificity protein (Sp) family transcription factors play a critical role in various cellular processes and have been shown to be associated with tumorigenesis. The Sp family consists of several members that contain a highly conserved DNA-binding domain composed of three zinc fingers at the C-terminus and serine/threonine-and glutamine-rich transactivation domains at the N-terminal. Sp1 is elevated in several malignancies including prostate cancer and is associated with the prognosis of patients. Sp1, Sp3, and Sp4 regulate a variety of cancer associated genes that are involved in cell cycle, proliferation, cell differentiation, and apoptosis. Studies have shown that in prostate cancer, Sp1 regulates important genes like androgen receptor, TGF-β, c-Met, fatty acid synthase, matrix metalloprotein (MT1-MMP), PSA, and α-integrin. These results highlight the importance of Sp1 in prostate cancer and emphasize the potential therapeutic value of targeting Sp1. Several strategies, including the use of natural and synthetic compounds, have been used to inhibit Sp1 in prostate cancer. These include polyphenol quercetin, betulinic acid, acetyl-11-keto-beta-boswellic acid, tea phenols, isothiocyanates, thiazolidinediones, arsenic trioxide, and selenium. This review will describe the association of Sp1 in prostate cancer with a special emphasis on some of the agents tested to target Sp1 for the treatment of this malignancy.",
keywords = "Cancer therapy, Prostate cancer, PSA, Sp transcription factors",
author = "Sankpal, {Umesh T.} and Steven Goodison and Maen Abdelrahim and Riyaz Basha",
year = "2011",
month = "9",
day = "1",
doi = "10.2174/157340611796799203",
language = "English (US)",
volume = "7",
pages = "518--525",
journal = "Medicinal Chemistry",
issn = "1573-4064",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Targeting Sp1 transcription factor in prostate cancer therapy

AU - Sankpal, Umesh T.

AU - Goodison, Steven

AU - Abdelrahim, Maen

AU - Basha, Riyaz

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Transcription factors are proteins that regulate gene expression by binding to specific DNA sequences within gene promoter regions. Specificity protein (Sp) family transcription factors play a critical role in various cellular processes and have been shown to be associated with tumorigenesis. The Sp family consists of several members that contain a highly conserved DNA-binding domain composed of three zinc fingers at the C-terminus and serine/threonine-and glutamine-rich transactivation domains at the N-terminal. Sp1 is elevated in several malignancies including prostate cancer and is associated with the prognosis of patients. Sp1, Sp3, and Sp4 regulate a variety of cancer associated genes that are involved in cell cycle, proliferation, cell differentiation, and apoptosis. Studies have shown that in prostate cancer, Sp1 regulates important genes like androgen receptor, TGF-β, c-Met, fatty acid synthase, matrix metalloprotein (MT1-MMP), PSA, and α-integrin. These results highlight the importance of Sp1 in prostate cancer and emphasize the potential therapeutic value of targeting Sp1. Several strategies, including the use of natural and synthetic compounds, have been used to inhibit Sp1 in prostate cancer. These include polyphenol quercetin, betulinic acid, acetyl-11-keto-beta-boswellic acid, tea phenols, isothiocyanates, thiazolidinediones, arsenic trioxide, and selenium. This review will describe the association of Sp1 in prostate cancer with a special emphasis on some of the agents tested to target Sp1 for the treatment of this malignancy.

AB - Transcription factors are proteins that regulate gene expression by binding to specific DNA sequences within gene promoter regions. Specificity protein (Sp) family transcription factors play a critical role in various cellular processes and have been shown to be associated with tumorigenesis. The Sp family consists of several members that contain a highly conserved DNA-binding domain composed of three zinc fingers at the C-terminus and serine/threonine-and glutamine-rich transactivation domains at the N-terminal. Sp1 is elevated in several malignancies including prostate cancer and is associated with the prognosis of patients. Sp1, Sp3, and Sp4 regulate a variety of cancer associated genes that are involved in cell cycle, proliferation, cell differentiation, and apoptosis. Studies have shown that in prostate cancer, Sp1 regulates important genes like androgen receptor, TGF-β, c-Met, fatty acid synthase, matrix metalloprotein (MT1-MMP), PSA, and α-integrin. These results highlight the importance of Sp1 in prostate cancer and emphasize the potential therapeutic value of targeting Sp1. Several strategies, including the use of natural and synthetic compounds, have been used to inhibit Sp1 in prostate cancer. These include polyphenol quercetin, betulinic acid, acetyl-11-keto-beta-boswellic acid, tea phenols, isothiocyanates, thiazolidinediones, arsenic trioxide, and selenium. This review will describe the association of Sp1 in prostate cancer with a special emphasis on some of the agents tested to target Sp1 for the treatment of this malignancy.

KW - Cancer therapy

KW - Prostate cancer

KW - PSA

KW - Sp transcription factors

UR - http://www.scopus.com/inward/record.url?scp=80051975232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051975232&partnerID=8YFLogxK

U2 - 10.2174/157340611796799203

DO - 10.2174/157340611796799203

M3 - Review article

C2 - 22022994

AN - SCOPUS:80051975232

VL - 7

SP - 518

EP - 525

JO - Medicinal Chemistry

JF - Medicinal Chemistry

SN - 1573-4064

IS - 5

ER -